ment with either 2 or 8 mg/kg N-hexacosanol did not alter diabetic rat status, i.e., body weight, serum glucose or serum insulin levels, but it significantly reversed the decrease in tracheal wall thickness and diabetes-induced hypercontractility in the rat trachea. In the immunohistochemical studies, muscarinic M 2 and M 3 receptors were expressed in the airway smooth muscle, the elastic fibers, the fibroblast and the surface of epithelium, and these expressions were not altered by either induction of diabetes or N-hexacosanol treatment. The expression of M 3 muscarinic receptor mRNAs in the trachea tended to be increased by the induction of diabetes and normalized when treated with N-hexacosanol. Our data indicate that N-hexacosanol could reverse diabetes-induced hypercontractility in the rat trachea.
Introduction
The airway smooth muscle can be innervated by both the sympathetic and parasympathetic nerves. Stimulation of muscarinic receptors facilitates tracheal contraction. Five cholinergic muscarinic receptor subtypes (M 1 -M 5 ) have been identified on the basis of molecular cloning studies [1] . Furthermore, the five main subtypes (M 1 rinic receptors in the airways have been suggested to play an important role [2] [3] [4] [5] [6] . Stimulation of neuronal M 2 muscarinic receptors has been shown to inhibit acetylcholine release and to decrease bronchoconstriction [2] [3] [4] , and blocking of neuronal M 2 muscarinic receptors enhances acetylcholine release and increases bronchoconstriction [2, 3, 5, 6] . Peripheral neuropathy caused by sensory neural dysfunction is among the most common complications of diabetes mellitus. Several epidemiological studies have reported that patients with type 1 diabetes have a low incidence of asthma [7] , although the mechanism behind this relation remains obscure. Belmonte et al. [8, 9] reported that the neuronal M 2 muscarinic receptors are hyperfunctional in the airways of diabetic rats, which decreases bronchoconstriction. Coulson et al. [10] also reported that neuronal M 2 muscarinic receptors are hyperfunctional in the trachea of diabetic rats. The function of post-junctional M 3 muscarinic receptors in the trachea and airways was also increased in diabetes [8, 10] . Other studies have reported that the activity of M 3 muscarinic receptors in the trachea and airways is also increased animal models of diabetes [8, 10] .
Cyclohexenonic long-chain fatty alcohol exhibits a wide variety of biological actions. The C26-alcohol, Nhexacosanol, directly increases the neurite extension and the biochemical differentiation of cultured cerebral neurons [11, 12] . Azzouz et al. [13] reported that N-hexacosanol increases the regeneration of both sensory and motor axons in lesioned nerves, leading to an important functional recovery. Some studies have indicated that Nhexacosanol exerts neurotrophic effects on cultured cerebral neurons [11, 14, 15] . Previous studies have demonstrated that N-hexacosanol prevents diabetes-induced hypercontractility of the trachea, cystopathy, and angiopathy [16] [17] [18] . Watanabe and Miyagawa [16] reported that N-hexacosanol exerts beneficial effects on peripheral neuropathy and cystopathy in diabetes-induced rats, and they suggested that the normalization of motor sciatic nerve conduction might be responsible for these effects. In addition, we previously reported that N-hexacosanol had ameliorative effects on diabetes-induced hypercontractility of the bladder, trachea and aorta in experimental rats [17] [18] [19] . However, it remains unclear whether N-hexacosanol has the ability to reverse diabetes-induced hypercontractility in the rat trachea. Furthermore, there is no information available about the mechanism and distribution of muscarinic M 2 and M 3 receptors in the rat trachea or whether induction of diabetes alters this distribution.
In this study, we tried to elucidate the distribution of muscarinic M 2 and M 3 receptors and whether treatment with N-hexacosanol is able to reverse diabetes-induced hypercontractility in the rat trachea.
Materials and Methods

Animal Model
All animal experiments were performed in accordance with the guidelines established by the Tottori University Committee for Animal Experimentation. Eight-week-old male Sprague-Dawley rats weighing 240-260 g were obtained from Japan SLC (Shizuoka, Japan). Rats were housed in a room maintained at 23 8 2 ° C, and exposed to a 12-hour dark/light cycle. The animals had unlimited access to standard laboratory diet and tap water. Our experimental protocol is shown in figure 1 . Diabetes was induced by administering a single intraperitoneal (i.p.) injection of 50 mg/ kg streptozotocin (STZ) dissolved in a 0.1-mol/l citrate-phosphate buffer (pH 4.2), according to the method in our previous reports [17] [18] [19] [20] [21] . Non-diabetic control rats received an injection of citratephosphate buffer alone. Two days after the injection of STZ or vehicle, we confirmed the induction of diabetes by measuring urinary glucose with Pretest 3a II (Wako Pure Chemical, Osaka, Japan). Four weeks after the induction of diabetes, rats were randomly divided into 5 groups: age-matched non-diabetic control rats (group A); 4-week diabetic rats without N-hexacosanol treatment (group B); diabetic rats treated with vehicle (group C), and diabetic rats treated with N-hexacosanol at a dose of 2 or 8 mg/kg i.p. every day for the following 4 weeks (group D and group E, respectively; n = 6-8 animals in each group). All rats were treated with N-hexacosanol or vehicle i.p. every day, according to the method described in our previous report [19] . N-hexacosanol was dissolved in ethanol, and then we added a mixture of physiological saline/Tween 80 according to the following ratio: ethanol/saline/Tween 80 = 5/92.15/2.85. Eight weeks after the induction of diabetes, the rats were killed with an overdose of pentobarbital (60 mg/rat, i.p.). Blood samples were obtained from the vena cava, and the tracheas were harvested and placed in a Krebs-Henseleit solution with the following composition (mmol/l): NaCl 118.0, KCl 4.7, MgSO 4 1.2, CaCl 2 2.5, KH 2 PO 4 1.2, NaHCO 3 24.9, glucose 5.6, and sodium pyruvate 2.0.
Serum Glucose and Insulin Measurement
The serum glucose concentrations in the experimental rats were measured by the hexokinase method (Glucose CII; Wako Pure Chemical Co., Osaka, Japan), which was carried out according to the manufacturer's instructions. The insulin concentrations were also measured by enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions (Rat Insulin ELISA; Mercodia AB, Uppsala, Sweden).
Tissue Preparation and Measurement of Contractile Force in the Isolated Trachea
The rat tracheas were cut into 3-4 cartilaginous rings. Each ring segment was mounted on a wire hook in an organ bath that contained 25 ml of Krebs-Henseleit solution, and bubbled with 5% CO 2 
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(type 45196A; San-ei Instruments, Tokyo, Japan), and the lower hook was fixed to a plastic support leg that was attached to a micrometer (Mitutoyo, Tokyo, Japan). Each ring was equilibrated unstretched for 30 min. A load of 0.5 g was applied to each ring by micrometer adjustment, and the load was readjusted to this level 30 min later. Changes in the tone of the rings were induced by means of a force transducer, and recorded on a personal computer (Macintosh G3; Apple Computer, Cupertino, Calif., USA) using Chart v 3.6.9 software and a PowerLab/16sp data acquisition system (AD Instruments, Castle Hill, Australia). In order to normalize the data to account for differences in tissue weight, the contractile response to carbachol was expressed as grams contractile force per milligram tissue weight. Cumulative dose-response curves to carbachol were recorded.
Morphology of the Rat Trachea
The tracheal tissue was immediately harvested and fixed in 10% formalin for 1 week. After fixation, the tissues were embedded in paraffin. Tissue sections (5 m thick) were cut from these paraffin blocks and stained with hematoxylin and eosin (HE). The sections were also subjected to immunohistochemical staining for muscarinic M 2 or M 3 receptors. Briefly, the sections were deparaffinized with xylene, and rehydrated through graded concentrations of ethanol. The slides were then incubated in 3% H 2 O 2 for 15 min at room temperature to block the endogenous peroxidase activity. Subsequently, tissue sections were overlaid with the 1: 500 dilution of rabbit anti-muscarinic M 2 receptor polyclonal antibody (Lot No. 24021674, Acris Antibodies GmbH, Hiddenhausen, Germany) or the 1: 250 dilution of rabbit anti-muscarinic M 3 receptor polyclonal antibody (Lot No. 25012152, Acris Antibodies GmbH) or control (rabbit) and then incubated overnight at 4 ° C. The specifically bound first antibodies were visualized by Histofine simple stain rat MAX-PO and Histofine simple stain DAB substrate kit (Nichirei Co., Tokyo, Japan). Negative controls were established for each group according to the procedure mentioned above, but without the Histofine simple stain rat MAX-PO.
After optimal color development, tissue sections were immersed in sterile water, counterstained with Mayer's hematoxylin (Nichirei Co., Tokyo, Japan), and cover-slipped. The tissue sections were observed with a light microscope (BX50; Olympus, Tokyo, Japan) and recorded using a digital camera (HC-3000; Fujix, Tokyo, Japan) at a magnification of ! 200-400.
Real-Time RT-PCR
Real-time polymerase chain reaction (PCR) was performed to measure muscarinic M 2 and M 3 receptor mRNAs in the experimental rat trachea. The mRNAs were purified by an RNeasy Mini Kit (Quiagen, Valencia, Calif., USA) according to the manufacturer's instructions. A reverse transcriptase (RT) mixture (28 l) containing 2 g of total RNA was made and incubated at 37 ° C for 60 min. 15 l of the mixture was used for real-time PCR, which was performed on a LightCycler thermal cycler system with a LightCycler-FastStart Hybridization Probe kit according to the manufacturer's instructions (Roche Diagnostics, Tokyo, Japan) [22] . The primer and probe sequences specific to the genes of M 2 or M 3 are described in table 1 . The primers and probes were synthesized commercially by Nihon Gene Research Labolatories Inc. The ␤ -actin primers and probes were taken from the LightCyclerPrimer/Probe Set (rat; Roche Diagnostics). A total of 5 l of template was used for the sample. The specificity of the reaction was confirmed by melting curve analysis and 2% agarose gel electrophoresis. The primers for the ␤ -actin gene were used as the internal standard and analyzed by real-time PCR using the same RT mixture. The reactions and runs for all samples were performed in duplicate.
Data Analysis
The ED 50 values were obtained by using a Macintosh computer (G3) loaded with Chart v 3.6.9 software and a PowerLab/ 16sp data acquisition system. The thickness of the tracheal wall was calculated by the following equation: tracheal wall thickness = weight/(the area of tracheal ring segments ! 1.05), where Fig. 1 . Experimental protocol. Rats were randomly divided into 4 groups: group A = age-matched non-diabetic control rats; group B = 4-week diabetic rats without N-hexacosanol treatment; group C = diabetic rats treated with vehicle alone; group D = diabetic rats treated with Nhexacosanol (2 mg/kg), and group E = diabetic rats treated with N-hexacosanol (8 mg/kg; n = 6-8 animals in each group).
1.05 is the assumed density of tracheal smooth muscle. All values are expressed as the mean 8 SEM. Differences between groups were examined for statistical significance by analysis of variance and Fisher's multiple comparison tests. Values of p ! 0.05 were considered to indicate a statistically significant difference.
Drugs and Chemicals
3-(15-Hydroxypentadecyl)-2,4,4-trimethyl-2-cyclohexen-1-one (N-hexacosanol) was obtained from Meiji Milk Products Co., Ltd. (Tokyo, Japan). Carbachol and pentobarbital were purchased from Sigma (St. Louis, Mo., USA). STZ was purchased from Wako Pure Chemical Co. (Osaka, Japan). All other chemicals were available commercially and of reagent grade.
Results
General Features of Experimental Animals
The data obtained regarding the general features and serum concentrations of insulin and glucose of the experimental animals are shown in table 2 . The diabetic rats treated both with and without N-hexacosanol showed no weight gain during the experimental period. The diabetic rats displayed significantly higher serum glucose and lower serum insulin levels than those of the controls. The thickness of the tracheal wall was significantly decreased by the induction of diabetes. The diabetes-induced reduction in tracheal wall thickness was significantly ameliorated not only by high-dose (8 mg/kg) but also low-dose (2 mg/kg) treatment with N-hexacosanol, and there was no significant difference between the effects by low-dose and high-dose treatment ( table 2 ) . Treatment with Nhexacosanol (at either 2 or 8 mg/kg) did not improve the general features of experimental animals. Moreover, this treatment did not alter serum glucose or insulin levels in the experimental diabetic animals. These data agree with our previous reports [17] [18] [19] .
Measurement of Contractile Response
The E max values for the contractile response of the trachea rings to carbachol were determined and are presented in table 3 and figure 2 . Diabetes-induced hypercontractility to carbachol was observed in the diabetic rat trachea. Diabetes-induced hypercontractility in the rat trachea was significantly ameliorated not only by highdose (8 mg/kg) but also low-dose (2 mg/kg) treatment with N-hexacosanol, and there was no significant difference between the effect of low-dose and high-dose treatment. The ED 50 values with respect to carbachol were decreased by the induction of diabetes and were significantly ameliorated not only by high-dose (8 mg/kg) but also low-dose (2 mg/kg) treatment with N-hexacosanol, and there was no significant difference between the effect of low-dose and high-dose treatment.
Morphology of the Rat Trachea
The typical HE staining results obtained upon histological examination are shown in figure 3 . Either the induction of diabetes or the treatment with N-hexacosanol (both high and low doses) did not significantly affect histological examinations, i.e., thinning of cricoid cartilage, thickness of basal membrane, smooth muscle bundle, surface of epithelium and inflammatory cells.
Immunohistochemical Stains for Muscarinic M 2 and M 3 Receptors
Typical results of the immunohistochemical staining for muscarinic M 2 and M 3 receptors of the rat trachea are shown in figure 3 . Histological examination of the staining for both muscarinic M 2 and M 3 receptors showed that the airway smooth muscle, the elastic fibers, the fibroblast and the surface of epithelium were stained, whereas the cricoid cartilage and the gland were not stained. The Contractile responses to carbachol in the rat trachea. In order to normalize the data to account for differences in tissue weight, the contractile response to carbachol was expressed as grams contraction per milligram tissue weight. Group A = Control rats; group B = 4-week diabetic rats without N-hexacosanol treatment; group C = diabetic rats treated with vehicle alone; group D = diabetic rats treated with N-hexacosanol (2 mg/kg), and group E = diabetic rats treated with N-hexacosanol (8 mg/ kg). All values are expressed as the mean 8 SEM. The E max values for the contractile response to carbachol were determined. In order to normalize the data to account for differences in tissue weight, the contractile response to carbachol and KCl (100 mmol/l) is expressed as grams contractile force per milligram tissue weight. The ED 50 values are with respect to carbachol. Group A = Control rats; group B = 4-week diabetic rats without N-hexacosanol treatment; group C = diabetic rats treated with vehicle alone; group D = diabetic rats treated with N-hexacosanol (2 mg/kg), and group E = diabetic rats treated with N-hexacosanol (8 mg/kg).
All Table 4 shows the expressions of muscarinic M 3 receptor mRNAs in the experimental trachea as determined by real-time PCR analysis. The expressions of muscarinic M 3 receptor mRNAs in the experimental trachea tended to be increased by the induction of diabetes, and these increases tended to be decreased by both lowdose (2 mg/kg) and high-dose (8 mg/kg) treatment with N-hexacosanol, whereas there was no significant difference in the expression level of muscarinic M 3 receptor mRNAs in the trachea between any groups. M 2 receptor mRNA expression was not detected. Real-time PCR was not performed to measure muscarinic M 2 and M 3 receptor mRNAs in the rat trachea of group B, because we lacked a sufficient volume of rat tracheal tissue.
Real-Time RT-PCR
Discussion
In this study, we demonstrated that diabetes-induced hypercontractility in the rat trachea was partially reversed by treatment with N-hexacosanol. Interestingly, N-hexacosanol treatment did not affect the diabetic sta- Muscarinic M 3 receptor mRNAs were normalized with ␣-actin mRNAs. Group A = Control rats; group B = 4-week diabetic rats without N-hexacosanol treatment; group C = diabetic rats treated with vehicle alone; group D = diabetic rats treated with n-hexacosanol (2 mg/kg), and group E = diabetic rats treated with N-hexacosanol (8 mg/kg). Data are shown as mean 8 SEM of 8 separate determinations in each group. Real-time PCR was not performed to measure muscarinic M 2 and M 3 receptor mRNAs in the rat trachea of group B. tus of the rats, i.e., with respect to body weight, serum glucose levels, and serum insulin levels. Our data indicate that this drug can improve diabetes-induced hypercontractility in the rat trachea without affecting serum glucose and insulin levels.
In previous reports, N-hexacosanol increased the neurite extension as well as the biochemical differentiation of cultured cerebral neurons in vitro, promoted the survival of septal cholinergic neurons after fimbria-fornix transection, and reduced the neuronal damage induced by kainic acid in vivo [11, 14, 15] . Watanabe and Miyagawa [16] reported that N-hexacosanol exerts beneficial effects on peripheral neuropathy and cystopathy in STZ-induced diabetic rats. They also demonstrated that diabetes-induced alterations in motor sciatic nerve conduction could be normalized by treatment with N-hexacosanol. These data indicate that N-hexacosanol can exert neurotrophic effects not only in the central nervous system, but also in the peripheral nervous system. Furthermore, we have reported that diabetes-induced hypercontractility of the rat bladder, trachea and aorta were ameliorated by treatment with N-hexacosanol [17, 18, 19] .
Previously, we reported that preventive treatment with N-hexacosanol ameliorated diabetes-induced hypercontractility and the thickness of the tracheal wall in rats [17] . In the present study, both diabetes-induced tracheal hypercontractility to carbachol and diabetes-induced thickening of the tracheal wall were significantly ameliorated by both low-dose (2 mg/kg) and high-dose (8 mg/ kg) treatment with N-hexacosanol. We found that treatment with N-hexacosanol could reverse both diabetesinduced hypercontractility in the trachea and thickening of the tracheal wall. In the present study, we performed a histological examination of rat tracheal sections stained with HE. However, the histology of the rat trachea was not altered by either the induction of diabetes or the Nhexacosanol treatment.
It is widely accepted that both muscarinic M 2 and M 3 receptors are expressed in the smooth muscle of the trachea [23] [24] [25] and play a role in diabetes mellitus [26] [27] [28] [29] . It has also been reported that muscarinic M 2 and M 3 receptors play an important role in the airway smooth muscle. Coulson et al. [10] reported that inhibitory muscarinic M 2 receptors on parasympathetic nerves in the trachea are hyperfunctional in diabetic rats and the function of post-junctional M 3 muscarinic receptors is also increased in diabetes, although the detailed mechanism by which diabetes induces this hyperfunctionality remains unclear. Treatment with N-hexacosanol, however, significantly improved diabetes-induced hypercontractility, possibly by ameliorating the overexpression of M 3 muscarinic receptors and their mRNAs.
In our present study, in order to investigate the distribution of muscarinic M 2 and M 3 receptors, we used immunohistochemical staining to examine the histology of the rat trachea. Our results suggest that the distributions of muscarinic M 2 receptors are similar to those of muscarinic M 3 receptors, and that both muscarinic M 2 and M 3 receptors exist on the airway smooth muscle, the elastic fibers, the fibroblast, the surface of epithelium. The distributions of M 2 and M 3 receptors were not altered by either the induction of diabetes or the treatment with Nhexacosanol.
There have been very few studies on muscarinic M 2 and M 3 receptors in the trachea at the mRNA level. In order to elucidate whether treatment with N-hexacosanol alters the expression of M 2 and M 3 receptor mRNAs in the rat trachea, we performed real-time PCR analysis. Our results show that the expression of M 3 receptor mRNAs in the trachea tend to be higher in the diabetic group treated with vehicle alone than in the control group, and tend to be lower in both the low-and high-dose Nhexacosanol treatment groups than in the diabetic group treated with vehicle alone. The present study shows that M 2 receptor mRNA expression was not detected. Saito et al. [30] and Shinbori et al. [31] demonstrated that the expression of M 3 receptor mRNAs was about 10-to 25-fold greater than that of M 2 receptor mRNAs in the rat bladder, and the expression of M 3 receptor mRNA was about 100-fold greater than that of M 2 receptor mRNA in the rat ileum. In this study, since we performed not only a real-time PCR analysis but also a functional study and a histological examination, we lacked a sufficient volume of rat tracheal tissue to measure M 2 and M 3 receptor mRNAs. Although these findings did not reach the level of statistical significance because of the large standard errors and real-time PCR analysis was not performed in the trachea of -week diabetic rats without N-hexacosanol treatment, it is possible that the overexpression of M 3 receptor mRNAs induced an upregulation of the expression of a muscarinic M 3 subtype that is involved in hypercontractility of the tracheal smooth muscle in diabetic rats. It is possible that N-hexacosanol reverses the overexpression of M 3 receptor mRNAs.
Girlanda-Junges et al. [32] and Gonzalez de Aguilar et al. [12] demonstrated that N-hexacosanol enhanced arginine vasopressin release from nerve terminals and also exhibited neurotrophic properties. Jover et al. [33] also reported that the compound had an effect on the presence of extracellular calcium ions, but not on transmembrane voltage-operated calcium channels. Thus, although there have been several molecular level reports on N-hexacosanol, the physiological and pharmacological mechanisms of this drug are not fully understood. From our previous data and those in the literature, it is possible that diabetes-associated neuropathy reduces the release of acetylcholine from the cholinergic nerve, and that muscarinic receptors are overexpressed in the diabetic trachea. Although further studies are necessary, it is possible that treatment with N-hexacosanol could reverse diabetes-induced hypercontractility in the rat trachea by regulating the expression level of muscarinic M 3 receptor mRNAs.
Conclusions
1 Treatment with N-hexacosanol did not alter body weight, serum glucose or insulin levels in the present rat model of diabetes mellitus. 2 The contractile responses of tracheal rings to carbachol were increased by induction of diabetes, and this effect was significantly normalized by treatment with N-hexacosanol. 3 Diabetes induced thickening of the tracheal wall, and this effect was significantly ameliorated by treatment with N-hexacosanol. 4 Muscarinic M 2 and M 3 receptor subtypes were distributed throughout the airway smooth muscle, the elastic fibers, the fibroblast and the surface of epithelium, and the distribution of these receptors was not altered by either the induction of diabetes or treatment with Nhexacosanol. 5 Real-time PCR analysis showed that the expression level of M 3 receptor mRNAs in the trachea tended to be increased in the diabetic group treated with vehicle alone and that this increase tended to be ameliorated in the N-hexacosanol treatment groups. M 2 receptor mRNA expression was not detected. 6 N-Hexacosanol could reverse the diabetes-induced hypercontractility of the rat trachea.
